Related Experiment Videos
Yolk sac carcinoma of the testis in children
Insights
For young children with localized yolk sac tumors, retroperitoneal node dissection, radiation, or chemotherapy are not beneficial. Successful treatment for advanced or recurrent disease involves chemotherapy and potentially radiation therapy.
Area of Science:
- Pediatric Oncology
- Urologic Oncology
- Cancer Research
Background:
- Yolk sac carcinoma of the testis is a rare malignancy in young children.
- Early diagnosis and treatment are crucial for favorable outcomes.
Purpose of the Study:
- To evaluate the effectiveness of different treatment modalities for localized and advanced yolk sac carcinoma of the testis in pediatric patients.
- To identify optimal management strategies based on disease stage and patient outcomes.
Main Methods:
- Retrospective review of 11 pediatric patients diagnosed with yolk sac carcinoma between 1971 and 1983.
- Analysis of treatment approaches including radical inguinal orchiectomy, retroperitoneal node dissection, chemotherapy, and radiation therapy.
- Correlation of treatment outcomes with disease stage, serum alpha-fetoprotein levels, and patient survival.
Main Results:
- All 11 patients underwent radical inguinal orchiectomy. None of the 4 patients with retroperitoneal node dissection showed tumor spread.
- 3 of 5 patients with localized disease and no further treatment survived without evidence of disease.
- Postoperative chemotherapy in 6 patients resulted in only 1 relapse. Of 3 patients with pulmonary metastases, 1 died of tumor and 1 of treatment complications.
- Patients with localized disease and normal postoperative alpha-fetoprotein levels did not benefit from further interventions like RPLND, irradiation, or chemotherapy.
Conclusions:
- Retroperitoneal node dissection, postoperative abdominal irradiation, and chemotherapy are not beneficial for pediatric patients with localized yolk sac carcinoma and normal postoperative serum alpha-fetoprotein levels.
- Chemotherapy, sometimes combined with radiation therapy, can successfully treat patients with retroperitoneal nodal involvement, metastatic disease, or recurrent disease.
- Risk stratification based on disease stage and biomarkers is essential for tailoring treatment and improving survival in pediatric testicular yolk sac carcinoma.
Abstract:
We reviewed the records of 11 patients with yolk sac carcinoma of the testis seen at the Children's Hospital of Philadelphia from 1971 through 1983. Each child was less than 2 years old at diagnosis, and each had stage I disease (localized to the testicle). Initial management consisted of radical inguinal orchiectomy in all 11 patients. Four patients then underwent retroperitoneal node dissection and none had pathological evidence of retroperitoneal tumor spread. After primary surgical management 5 patients received no further initial treatment. Of these 5 patients 3 are alive with no evidence of disease at 1.5, 2.7 and 4.5 years after diagnosis. The tumor recurred in 2 patients, 1 of whom was salvaged with pulmonary radiation therapy and chemotherapy. The other 6 patients received chemotherapy postoperatively and only 1 has suffered relapse. Over-all, of 3 patients in whom pulmonary metastases developed 1 died of tumor and 1 died of treatment-related pneumonopathy. Our experience and that of others have led us to conclude that patients with localized disease and normal postoperative serum alpha-fetoprotein levels do not benefit from retroperitoneal node dissection, postoperative abdominal irradiation or chemotherapy. Patients with retroperitoneal nodal involvement, widely metastatic disease or recurrent disease can be treated successfully with chemotherapy and in some cases with radiation therapy.